BiotechTube

Hydroxyurea

ApprovedTerminated
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Polycythemia Vera

Conditions

Polycythemia Vera

Trial Timeline

Jul 28, 2023 → Feb 26, 2026

NCT ID
NCT05853458

About Hydroxyurea

Hydroxyurea is a approved stage product being developed by Novartis for Polycythemia Vera. The current trial status is terminated. This product is registered under clinical trial identifier NCT05853458. Target conditions include Polycythemia Vera.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT05285917Phase 3Recruiting
NCT05853458ApprovedTerminated

Competing Products

20 competing products in Polycythemia Vera

See all competitors
ProductCompanyStageHype Score
Sapablursen + PlaceboOno PharmaceuticalPhase 3
77
Ruxolitinib + AbemaciclibEli LillyPhase 1
33
BomedemstatMerckPhase 2
52
Ruxolitinib + Hydroxycarbamide + Interferon-AlphaNovartisPhase 3
77
ruxolitinib tabletsNovartisPhase 3
77
RuxolitinibNovartisPre-clinical
23
RuxolitinibNovartisPhase 3
77
Ruxolitinib + BATNovartisPhase 2
52
Best Available Therapy + RuxolitinibNovartisPhase 3
77
Smac Mimetic LCL161NovartisPhase 2
52
PEGASYS + AspirinRochePhase 2
52
RG7388 + PegasysRochePhase 1
33
IdasanutlinRochePhase 2
52
PEGASYS + Hydroxyurea + AspirinRochePhase 3
77
Ropeginterferon alfa-2bPharmaEssentiaPhase 2
51
Pegylated-Proline-Interferon alpha-2b in a Pre-filled PenPharmaEssentiaPhase 3
76
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)PharmaEssentiaPhase 3
76
Ropeginterferon alfa-2bPharmaEssentiaApproved
84
P1101 + Low-dose aspirinPharmaEssentiaPhase 2
51
P1101 (Ropeginterferon alfa-2b)PharmaEssentiaPhase 3
76

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85